These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 12692051)

  • 1. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.
    Kellow J; Lee OY; Chang FY; Thongsawat S; Mazlam MZ; Yuen H; Gwee KA; Bak YT; Jones J; Wagner A
    Gut; 2003 May; 52(5):671-6. PubMed ID: 12692051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome.
    Nyhlin H; Bang C; Elsborg L; Silvennoinen J; Holme I; Rüegg P; Jones J; Wagner A
    Scand J Gastroenterol; 2004 Feb; 39(2):119-26. PubMed ID: 15000272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.
    Wagstaff AJ; Frampton JE; Croom KF
    Drugs; 2003; 63(11):1101-20. PubMed ID: 12749744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
    Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.
    Novick J; Miner P; Krause R; Glebas K; Bliesath H; Ligozio G; Rüegg P; Lefkowitz M
    Aliment Pharmacol Ther; 2002 Nov; 16(11):1877-88. PubMed ID: 12390096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
    Tegaserod Clinical Research Group
    Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
    Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
    Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.
    Fidelholtz J; Smith W; Rawls J; Shi Y; Zack A; Rüegg P; Lefkowitz M
    Am J Gastroenterol; 2002 May; 97(5):1176-81. PubMed ID: 12014724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.
    Fock KM; Wagner A;
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1190-8. PubMed ID: 17524039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.
    Müller-Lissner SA; Fumagalli I; Bardhan KD; Pace F; Pecher E; Nault B; Rüegg P
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1655-66. PubMed ID: 11564007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial.
    Johanson JF; Wald A; Tougas G; Chey WD; Novick JS; Lembo AJ; Fordham F; Guella M; Nault B
    Clin Gastroenterol Hepatol; 2004 Sep; 2(9):796-805. PubMed ID: 15354280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.
    Tougas G; Snape WJ; Otten MH; Earnest DL; Langaker KE; Pruitt RE; Pecher E; Nault B; Rojavin MA
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1701-8. PubMed ID: 12269961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
    Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
    Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.
    Morganroth J; Rüegg PC; Dunger-Baldauf C; Appel-Dingemanse S; Bliesath H; Lefkowitz M
    Am J Gastroenterol; 2002 Sep; 97(9):2321-7. PubMed ID: 12358251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care.
    Layer P; Keller J; Mueller-Lissner S; Rüegg P; Loeffler H
    Digestion; 2005; 71(4):238-44. PubMed ID: 16024929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome.
    Fried M; Beglinger C; Bobalj NG; Minor N; Coello N; Michetti P;
    Eur J Gastroenterol Hepatol; 2005 Apr; 17(4):421-7. PubMed ID: 15756094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tegaserod.
    Scott LJ; Perry CM
    Drugs; 1999 Sep; 58(3):491-6; discussion 497-8. PubMed ID: 10493276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.